Advances in
treatment for Hodgkin Lymphoma (HL) have dramatically improved long-term
survival and life expectancy. Despite, survivors are prone to develop high-dose
radiotherapy late-onset neoplastic complications: the 30 years cumulative
incidence of a second malignancy is 30.7% (95% CI, 28.7-32.7).
Among them, solid
tumors account for up to 75–80% of all second malignancies, typically located
at the edges of prior radiation fields. Primary liver
cancer secondary to HL is significantly increased after mixed-modality
treatment, with a 2.6 folds Relative-Risk and 0.5 Absolute Excess Risk per
10,000 Person-Years.
When technically
resectable, surgery is recognized to be the best curative treatment for primary
liver tumors. The downside is that surgery on radiation tissues is highly
dangerous leading to poor wound healing, fistula formation, skin necrosis and
even death in relation with atrophic tissue inefficient to realize normal
healing.
No comments:
Post a Comment